Outcome and validation of a new clinically based staging system for predicting survival of perihilar cholangiocarcinoma patients.

The clinical staging system has a limited performance in differentiating stage II pCCA patients from stage III patients in the Thai cohort. This can be due to differences in patient characteristics and treatment modalities between the Asian and White pCCA populations. However, the median survivals of patients with other stages are significantly different.